Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-Blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN, AZD2171) in Combination With 5-Fluorouracil, Leucovorin [folinic-acid], and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer.

X
Trial Profile

A Randomised, Double-Blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN, AZD2171) in Combination With 5-Fluorouracil, Leucovorin [folinic-acid], and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer.

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cediranib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms HORIZON-III
  • Sponsors AstraZeneca; AstraZeneca AB
  • Most Recent Events

    • 21 Jan 2023 Results of retrospective exploratory analysis were presented at the 2023 Gastrointestinal Cancers Symposium.
    • 25 Jan 2020 Results assessing the patterns of opioid use, and evaluating the impact of opioid use on survival outcomes among patients with advanced GI cancers who were included in eight clinical trials (NCT01124786; NCT00844649; NCT00290966; NCT00678535; NCT00699374; NCT00272051; NCT00305188; NCT00384176) presented at the 2020 Gastrointestinal Cancers Symposium
    • 23 Jun 2019 Trial has been completed in UK, according to European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top